0244 GMT - Ansell's bulls at Jefferies reckon the Australia-listed company will have pricing power if U.S. tariffs are imposed on medical personal-protective equipment. Analysts Vanessa Thomson and David Stanton tell clients in a note that strong brand recognition and the unfavorable economics around onshore production should allow Ansell to continue its policy of offsetting tariff impacts through higher prices. While waiting for clarity on healthcare PPE tariffs, Ansell's track record on this front bodes gives them confidence that it can complete its current phase of tariff-related price rises. Jefferies lifts its target price by 10% to A$43.00 and keeps a buy rating on the stock, which is down 0.6% at A$36.105. (stuart.condie@wsj.com)
(END) Dow Jones Newswires
October 29, 2025 22:44 ET (02:44 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.